July 21, 2015 Synthetic Biologics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option
June 29, 2015 Synthetic Biologics' Initiates SYN-010 Phase 2 Clinical Trial to Treat Irritable Bowel Syndrome with Constipation (IBS-C)
June 12, 2015 First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile
June 3, 2015 Synthetic Biologics Presents Initial Data Validating Platform Expansion to Cover Carbapenem Antibiotics
June 2, 2015 Synthetic Biologics Expands Clinical & Regulatory Leadership Team with Addition of Klaus Gottlieb, MD, FACG
May 19, 2015 Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted in Late-Breaking Poster at Digestive Disease Week® 2015
